newsfilter
← Latest News
ACCESS Newswire·

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX